menu
    • menu
    [{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"Acetylcholinesterase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dexa Medica \/ Dexa Medica","highestDevelopmentStatusID":"6","companyTruncated":"Dexa Medica \/ Dexa Medica"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDONESIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DLBS5055","moa":"Blood glucose level","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Dexa Medica","highestDevelopmentStatusID":"11","companyTruncated":"Dexa Medica \/ Dexa Medica"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Equilab International","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Dexa Medica \/ Equilab International","highestDevelopmentStatusID":"6","companyTruncated":"Dexa Medica \/ Equilab International"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Equilab International","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Dexa Medica \/ Equilab International","highestDevelopmentStatusID":"6","companyTruncated":"Dexa Medica \/ Equilab International"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DLBS1033","moa":"Fibrinolytic protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Dexa Medica \/ Dexa Medica","highestDevelopmentStatusID":"11","companyTruncated":"Dexa Medica \/ Dexa Medica"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDONESIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DLBS2411","moa":"Gastric acid secretion","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDONESIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Dexa Medica","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Dexa Medica"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDONESIA","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"Dexa Medica \/ Debiopharm","highestDevelopmentStatusID":"15","companyTruncated":"Dexa Medica \/ Debiopharm"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Equilab International","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Dexa Medica \/ Equilab International","highestDevelopmentStatusID":"1","companyTruncated":"Dexa Medica \/ Equilab International"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"University of Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDONESIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Predimenol","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ University of Indonesia","highestDevelopmentStatusID":"8","companyTruncated":"Dexa Medica \/ University of Indonesia"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Equilab International","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDONESIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Proliverenol","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Equilab International","highestDevelopmentStatusID":"8","companyTruncated":"Dexa Medica \/ Equilab International"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"University of Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDONESIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Reconyl","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ University of Indonesia","highestDevelopmentStatusID":"8","companyTruncated":"Dexa Medica \/ University of Indonesia"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"University of Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Silfamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dexa Medica \/ University of Indonesia","highestDevelopmentStatusID":"8","companyTruncated":"Dexa Medica \/ University of Indonesia"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Striatin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Dexa Medica","highestDevelopmentStatusID":"1","companyTruncated":"Dexa Medica \/ Dexa Medica"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Striatin Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dexa Medica \/ Dexa Medica","highestDevelopmentStatusID":"10","companyTruncated":"Dexa Medica \/ Dexa Medica"}]

    Find Clinical Drug Pipeline Developments & Deals by Dexa Medica

    Menu

    Dexa Medica

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Striatin Extract

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Recipient : Universitas Sriwijaya

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Striatin in Malnourished Children

                            Details : Striatin Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Severe Acute Malnutrition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 28, 2025

                            Lead Product(s) : Striatin Extract

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Recipient : Universitas Sriwijaya

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DLBS1033

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase IV

                            Recipient : Universitas Sebelas Maret

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Lumbrokinase DLBS1033 vs Betahistine in Benign Paroxysmal Positional Vertigo

                            Details : DLBS1033 is a drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Benign Paroxysmal Positional Vertigo.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 20, 2025

                            Lead Product(s) : DLBS1033

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase IV

                            Recipient : Universitas Sebelas Maret

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Striatin

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Recipient : Indonesia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Channa Striata Extract on Intestinal Inflammation and Nutritional Status in Malnutritional Toddlers...

                            Details : Striatin is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Malnutrition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            April 18, 2025

                            Lead Product(s) : Striatin

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Recipient : Indonesia University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apixaban

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Equilab International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Apixaban 5 mg Film-Coated Tablet

                            Details : Apixaban is a HPAPI drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            February 10, 2025

                            Lead Product(s) : Apixaban

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Equilab International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Hydrobromide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers

                            Details : Galantamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Galantamine Hydrobromide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamsulosin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets

                            Details : Tamsulosin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Tamsulosin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets

                            Details : Rivaroxaban is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Equilab International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Rivaroxaban 10 mg Film-coated Tablets

                            Details : Rivaroxaban is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Equilab International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Predimenol

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : University of Indonesia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Predimenol for Headache

                            Details : Predimenol is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Headache.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Predimenol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : University of Indonesia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Dexa Medica

                            Indonesia arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triptorelin Pamoate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Recipient : RSPAD Gatot Soebroto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect GnRH Agonist Administration in Endometriosis Cyst Patients

                            Details : Triptorelin Embonate is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometriosis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 29, 2024

                            Lead Product(s) : Triptorelin Pamoate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Recipient : RSPAD Gatot Soebroto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth